Policy Considerations as Children Ages 5-11 Become Eligible for the COVID-19 Vaccine

A new KFF issue brief lays out key factors for the successful rollout of COVID-19 vaccinations for younger children, ages 5 to 11. This week, the Food and Drug Administration’s (FDA) advisory committee will meet to vote on a request to authorize the Pfizer vaccine for younger children. A final FDA decision, and Centers for Disease Control and Prevention actions, will follow as soon as the first week in November.

As the Biden administration plans with states and local jurisdictions for rollout, among several issues to consider:

Read the brief, Vaccinating Children Ages 5-11: Policy Considerations for COVID-19 Vaccine Rollout, for a full discussion of implementation issues. Also available is KFF’s latest installment of the THE CONVERSATION / LA CONVERSACIÓN campaign addressing questions about the COVID-19 vaccines and children, with FAQ videos featuring pediatricians presented with the American Academy of Pediatrics.

Contact

Rakesh Singh
rsingh@kff.org
Craig Palosky
cpalosky@kff.org
Exit mobile version